vs
Side-by-side financial comparison of Acadian Asset Management Inc. (AAMI) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
Acadian Asset Management Inc. is the larger business by last-quarter revenue ($172.2M vs $86.8M, roughly 2.0× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 2.6%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 27.6%).
United Asset Management was an American holding company headquartered in Boston, Massachusetts.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
AAMI vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $172.2M | $86.8M |
| Net Profit | $34.7M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 33.3% | -84.7% |
| Net Margin | 20.2% | — |
| Revenue YoY | 2.6% | 17.7% |
| Net Profit YoY | -18.4% | — |
| EPS (diluted) | $0.97 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $172.2M | $86.8M | ||
| Q3 25 | $144.2M | $67.5M | ||
| Q2 25 | $127.4M | $60.0M | ||
| Q1 25 | $119.9M | $49.3M | ||
| Q4 24 | $167.8M | $73.7M | ||
| Q3 24 | $123.1M | $58.6M | ||
| Q2 24 | $109.0M | $31.1M | ||
| Q1 24 | $105.7M | $715.0K |
| Q4 25 | $34.7M | — | ||
| Q3 25 | $15.1M | $-91.3M | ||
| Q2 25 | $10.1M | $-111.7M | ||
| Q1 25 | $20.1M | $-116.2M | ||
| Q4 24 | $42.5M | — | ||
| Q3 24 | $16.9M | $-83.5M | ||
| Q2 24 | $11.0M | $-97.1M | ||
| Q1 24 | $14.6M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 33.3% | -84.7% | ||
| Q3 25 | 18.4% | -140.7% | ||
| Q2 25 | 12.7% | -189.8% | ||
| Q1 25 | 26.6% | -245.8% | ||
| Q4 24 | 38.7% | -117.5% | ||
| Q3 24 | 21.9% | -152.1% | ||
| Q2 24 | 18.9% | -327.6% | ||
| Q1 24 | 21.7% | -16464.6% |
| Q4 25 | 20.2% | — | ||
| Q3 25 | 10.5% | -135.3% | ||
| Q2 25 | 7.9% | -186.2% | ||
| Q1 25 | 16.8% | -235.5% | ||
| Q4 24 | 25.3% | — | ||
| Q3 24 | 13.7% | -142.7% | ||
| Q2 24 | 10.1% | -312.2% | ||
| Q1 24 | 13.8% | -15800.8% |
| Q4 25 | $0.97 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.28 | $-0.33 | ||
| Q1 25 | $0.54 | $-0.36 | ||
| Q4 24 | $1.11 | $-0.24 | ||
| Q3 24 | $0.45 | $-0.28 | ||
| Q2 24 | $0.29 | $-0.34 | ||
| Q1 24 | $0.37 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | $200.0M | — |
| Stockholders' EquityBook value | — | $698.6M |
| Total Assets | $677.0M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M | ||
| Q1 24 | — | $356.2M |
| Q4 25 | $200.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $275.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $698.6M | ||
| Q3 25 | — | $702.3M | ||
| Q2 25 | — | $698.5M | ||
| Q1 25 | — | $767.9M | ||
| Q4 24 | — | $710.4M | ||
| Q3 24 | — | $773.5M | ||
| Q2 24 | — | $768.5M | ||
| Q1 24 | — | $680.0M |
| Q4 25 | $677.0M | $913.2M | ||
| Q3 25 | $751.4M | $904.9M | ||
| Q2 25 | $672.3M | $907.4M | ||
| Q1 25 | $677.3M | $966.7M | ||
| Q4 24 | $703.2M | $910.4M | ||
| Q3 24 | $555.2M | $991.1M | ||
| Q2 24 | $533.1M | $964.3M | ||
| Q1 24 | $544.9M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.4M | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | -0.07× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.4M | $-52.6M | ||
| Q3 25 | $-23.9M | $-78.7M | ||
| Q2 25 | $61.6M | $-67.4M | ||
| Q1 25 | $-48.8M | $-103.7M | ||
| Q4 24 | $55.8M | $-73.3M | ||
| Q3 24 | $69.6M | $-59.0M | ||
| Q2 24 | $45.7M | $-98.4M | ||
| Q1 24 | $-40.4M | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 583.4% |
| Q4 25 | -0.07× | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | 6.10× | — | ||
| Q1 25 | -2.43× | — | ||
| Q4 24 | 1.31× | — | ||
| Q3 24 | 4.12× | — | ||
| Q2 24 | 4.15× | — | ||
| Q1 24 | -2.77× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAMI
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
